Actavis Outlines Standalone Pharma Pipeline - Quick Facts

(RTTNews) - Actavis plc (ACT), during its Investor Meeting in New York, provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth.

The company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

The company noted that it has committed to investing $1.7 billion in R&D in 2015 to support its continued brand and generic development initiatives. The company noted that its Global Generics R&D operations continued to lead the industry in 2014, with 42 ANDAs filed in the United States, 25 of which were confirmed as new first-to-file applications.

The Company said it continues to focus on the development of complex modified-release and other dosage forms that enhance its ability to offer distinctive products to customers around the world, and create sustainable long-term value.